Promising new rabies vaccine passes phase 3 test
NCT ID NCT03965962
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tested a new rabies vaccine (VRVg-2) in 640 healthy adults in France. Participants received the vaccine along with rabies immune globulin, mimicking a real post-exposure scenario. The study found that VRVg-2 produced protective antibody levels as effectively as two existing rabies vaccines. The results suggest VRVg-2 could be a safe and effective option for preventing rabies after exposure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Purified Vero Rabies Vaccine - Serum Free (VRVg-2)
What this could lead to
If successful, this could provide a new, safe, and effective rabies vaccine option for people exposed to the virus.
What could go wrong
This trial was completed in healthy adults in France, so results may not apply to everyone. Rabies is rare in developed countries, and the vaccine's performance in real-world exposure settings may differ.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RABIES (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 2500001
Rennes, 35000, France
-
Investigational Site Number 2500002
Gières, 38610, France